Panel Discussion: The Big Picture, Where Do We Stand and What's Next?
A Talk by Matthias von Herrath , Stephen Karpen , Jeffrey Siegel , Elisabeth Niemoeller , John Sharretts, MD and Jason Gaglia, MD, MMSc
About this Talk
The final discussion panel of the workshop will focus on conclusions and clarity. We will seek clarity as to the views of regulators regarding the use of C-peptide as an endpoint for trials in New-Onset T1D and conclusions as to what defined actions may need to be taken to resolve any lingering questions.
PANELISTS: FDA, Patient, Patient Advocacy, Academia, Industry, Physician
Moderators
Executive Director, Type 1 Diabetes Consortium, Critical Path Institute